secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001493152-23-003036
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce receives Nasdaq bid-price deficiency notice; 180-day cure period until July 26, 2023
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on Jan 27, 2023 for bid price closing below $1.00 for 30 consecutive business days.
- Has until July 26, 2023 to regain compliance; stock must close at $1.00+ for at least 10 business days.
- Similar deficiency was cured in Nov 2022 via a 1-20 reverse stock split; new non-compliance now also exists.
- Separate MVLS deficiency hearing held Jan 26, 2023; delisting stayed pending Panel decision with possible extension to June 12, 2023.
- Common stock continues to trade on Nasdaq under ENSC; no immediate delisting effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223003036/0001493152-23-003036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223003036/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-003036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer